KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Equity Ratio (2018 - 2025)

Historic Equity Ratio for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to 0.83.

  • Castle Biosciences' Equity Ratio fell 318.03% to 0.83 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.83, marking a year-over-year decrease of 318.03%. This contributed to the annual value of 0.86 for FY2024, which is 58.1% down from last year.
  • Per Castle Biosciences' latest filing, its Equity Ratio stood at 0.83 for Q3 2025, which was down 318.03% from 0.84 recorded in Q2 2025.
  • Castle Biosciences' Equity Ratio's 5-year high stood at 0.96 during Q1 2021, with a 5-year trough of 0.83 in Q3 2025.
  • Over the past 5 years, Castle Biosciences' median Equity Ratio value was 0.89 (recorded in 2021), while the average stood at 0.89.
  • As far as peak fluctuations go, Castle Biosciences' Equity Ratio skyrocketed by 3089.65% in 2021, and later crashed by 659.18% in 2022.
  • Castle Biosciences' Equity Ratio (Quarter) stood at 0.89 in 2021, then grew by 0.25% to 0.89 in 2022, then dropped by 3.27% to 0.86 in 2023, then decreased by 0.58% to 0.86 in 2024, then fell by 3.28% to 0.83 in 2025.
  • Its Equity Ratio stands at 0.83 for Q3 2025, versus 0.84 for Q2 2025 and 0.88 for Q1 2025.